Slides
Page 1
PRESENTATION INVESTOR December 2024 The company is listed on Warsaw Stock Exchange Translated from Polish to English - www.onlinedoctranslator.com
Page 2
Legal disclaimers This document has been prepared for informational purposes only, contains only summary information and is not intended to be exhaustive, nor is it intended to be the sole basis for any analysis or evaluation. Genomtec SA makes no representations (express or implied) regarding the information presented in this document and no reliance should be placed on any information contained in this document, including the forecasts, estimates and opinions contained therein. Genomtec SA assumes no liability for any errors, omissions or irregularities contained in this document. It uses sources of information that Genomtec SA considers reliable and accurate, but there is no guarantee that they are exhaustive and fully reflect the facts. This document does not constitute advertising or an offer of securities in public trading. The document may contain forward-looking statements that constitute an investment risk or a source of uncertainty and may differ materially from actual results. Genomtec SA is not responsible for the effects of decisions made on the basis of this document. The responsibility rests solely with the user of the document. The work is protected by the Copyright and Related Rights Act. Reproduction, publication or distribution requires written consent of Genomtec SA 2
Page 3
An international team, a combination of science and business MANAGEMENT Miron Tokarsky international team of 20 experts Chairman of the Management Board, Co-founder of the Company two locations: Wrocław and Kent (UK) Co-creator of Genomtec technology and patents Doctor of Medical Sciences in the field of molecular biology. Honored by Forbes in the "Leaders of the Future" ranking. CO-FOUNDERS Margaret Little-MasurianMichael Wachowski Chief Research Officer Member of the Management Board, Financial Director Over 10 years of experience in molecular biology. Head of the Department of Molecular Techniques at the Medical University of Wrocław. Author of scientific publications and co-author of Genomtec patents. 14+ years of experience in: corporate finance, investment management and business consulting. He was an investment director in a Venture Capital fund. Henryk Roguszczak Design Director Author of patents and over 80 domestic and foreign scientific publications. Previously an expert at the Wrocław University of Science and Technology at the Faculty of Microsystems, Electronics and Photonics. Coordinator of research activities in the field of photonics. 3
Page 4
Technology
Page 5
Genomtec SNAAT Delivering innovative diagnostic technologies close to the patient – Point of Care TEST SCOPE Infections Epidemiology Environmental testing TESTING LOCATION Clinics Doctor's offices Emergency Department Patient transportation Airports SNAAT technology Genomtec is a MedTech company specializing in the development of advanced genetic diagnostics technologies. 5
Page 6
What makes LAMP isothermal technology unique? PCR LAMP Requires temperature cycling Isothermal – one constant temperature Requires 2 starters Requires 6 starters Free: usually over 1 hour Fast: usually <30 min Requires a separate reverse transcription step Reverse transcription occurs together with the amplification step Typical yield approx. 0.2 μg Typical yield approx. 10-20 μg Sensitive to inhibitors from the biological sample - it is necessary cleaning Inhibitor-insensitive – native sample can be used biological Requires thermal denaturation The unraveling of the strands is caused by polymerase Compatible with both thermal cyclers and plate readers, and heating blocksRequires advanced thermal cycler It allows to detect a specific DNA fragment at the level nanogram (10-9g) It allows to detect a specific DNA fragment at the level femtogram (10-15g) Very high specificity due to greater coverage DNA/RNA segment amplified by primersHigh specificity 6
Page 7
oncoSNAAT Suspicion cancer Therapeutic decision Analytical phase Preparation libraries to sequencing Biopsy cancer Insulation DNA/RNA Analysis bioinformaticsBiopsy order Transport Sequencing Test result available for a doctor – application targeted therapy 48-72 hrs A few to a dozen weeks Analytical phase 10:23 21/09/2020 10:23 21/09/2020 10:23 21/09/2020 ID:TYU 78124x Mycoplasma pneumoniae Dophila's booze pneumoniae Flu A/B SARS-CoV-2= Ordering a study in at the moment of suspicion cancer Plasma transfer on the card Placing the card in device Test result available to the doctor – Application of therapy targeted Starting the analysis 7 Genomtec Current standard
Page 8
The effects of using isothermal technologies SPEED AND HIGH PRECISION MOBILITY VERSATILITY LOW COST ▪ High accuracy results ▪ Small analyzer dimensions and compact card microfluidic ▪ Identification of pathogens such as viruses and bacteria. ▪ Simplified construction microfluidic card▪ Carrying out multiple amplification reactions simultaneously (multiplexing) ▪ Possibility of use outside the laboratory (POCT) ▪ Identification of genetic variants (e.g. CDx, prediction). ▪ Relatively low cost of the analyzer and reagents ▪ Room temperature stability ▪ Lower cost of analysis thanks to multiplexing technology▪ Easy procedure conducting a study ▪ Possibility to connect multiple analyzers▪ Low energy requirements 8
Page 9
Change of structure organizational
Page 10
Changes in the organizational structure of the company in connection with the M&A process CURRENTLY: GENOMTEC SA. • Adjustment buyers downneeds One company carries out all projects • Accelerate M&A transactions • Increase in transaction value AFTER CHANGE: GENOMTEC SA. Parent company 100% 100% 100% GMT ID GMT CDx Food safety company The company implementing the project Genomtec ID A company implementing a security project food The company implementing the project Onco SNAAT 10
Page 11
Current activities operational
Page 12
M&A process status – synergy of business and R&D activities Several dozen meetings July 2023 - Present Building a list of interested parties Signing of contracts NDA Signing of confidentiality agreements with a number of interested entities. 5 areas interests Exchange of data regarding technologies offered by both parties to NDA agreements. • Environmental requirements and stability of use of the Genomtec ID platform (including temperature, humidity). • Costs of producing large-scale reaction cards. • Leverage amplification technologies owned by potential partners. • Diagnostics acceleration capabilities using Genomtec ID. (Q4 2024) • Methods for detecting genetic changes using isothermal technologies developed by Genomtec. (Q4 2024) 12
Page 13
The state of the M&A process – technology Environmental requirements and stability of use of the Genomtec ID platform (including temperature, humidity) • A series of tests and optimizations of algorithms controlling the non-contact heating system were carried out in an extended range of outside temperature and relative humidity. • Temperature stabilization was achieved atlevel +/- 0.15°Cwith a temperature difference between heating zones of up to 5°C. In combination with the use of 3 heating zones we managedcover the full temperature range for LAMP technology 60-70°C • Confirmedno influence of outside temperature changesandhumidityfrom the tested range on the efficiency of the heating system. • The stability of the heating system was confirmed between subsequent analyses. • The stability of the heating system over time has been confirmed. • Work on increasing the resolution of the heating system is coming to an end – more heating zones –greater accuracy of the analyses performed. 13
Page 14
The state of the M&A process – technology Possibilities of accelerating diagnostics using Genomtec ID. • In conjunction with the work focused on reducing the cost of producing the reaction card, at the request of one of the potential partners, the possibilities of using new reagents to shorten the test time were investigated. • It was carried outseveral thousand reactionsallowing the use of proprietary primers from the RP5-Plex panel (influenza A, influenza B, RSV A, RSV B, SARS-CoV-2, M. pneumoniae, Ch. pneumoniae) in combination with new enzymes. • The work also includes the development of a shortened protocol for isolating RNA viruses. • The above activities aim to create a panel of viral infections with TAT ~15 min. • As part of the work carried out, the amplification time in the LAMP technique was shortened to <10 min. for viral pathogens along with an improvement in the detection limit. Amplification curves for influenza A (top), B (middle) at 50 GE/reaction and for influenza A at 10,000 GE/reaction (bottom) • Work is underway to optimize a shortened procedure for isolating genetic material. 14
Page 15
Status of the M&A process – reduction of production costs Costs of producing large-scale reaction cards. • Discussions were held with a number of partners specializing in the production of lab-on-chip microfluidic systems. • Two independent quotes (CDMO partners) were obtained related to scaling up mid-scale production – semi-automatic line and large scale – automatic line. • In order to define the function of the production lines, it was necessary to determine the requirements related to the stabilization of reagents allowing them to be stored at room temperature. • Several hundred amplification reactions were performed to determine the impact of a number of stabilization processes on the diagnostic parameters of the tests. • The work carried out allowed us to determine the requirements for production lines, along with their equipment and costs. • Achieved over 70% reduction in production cost of card and reagents. • Work also focused on optimizing reagent costs. • Obtainedup to 80% reduction in reagent costs. 15
Page 16
Development of the Onco SNAAT project 500+ Conducted laboratory reactions Development of an original method for diagnosing single- nucleotide changes cftDNA IP Selection of sample volume parameters. Start of work on DNA isolation method. Actions aimed at obtaining and extending intellectual property protection. 21.6M PLN FENG PARP funding amount - completion of the grant project planned for the 1st half of 2027 The Genomtec project entitled: "Development of technology and an automatic system for detecting mutations in the field of clinical oncology based on the lab-on-chip solution and isothermal nucleic acid amplification techniques" was among 198 applications entered by PARP on the list of projects assessed positively in the SMART Path Measure FENG.01.01-IP.02-001/23/2023 under the European Funds for Modern Economy Programme. * The recommended amount of funding for the project is approximately PLN 21.6 million with a total project budget of approximately PLN 40 million. If funding is received, the project will be implemented in the period from January 2024 to June 2027. 16
Page 17
Market Potential food safety
Page 18
The State of the Microbiological Diagnostics Market • Pathogens such asSalmonella, Listeria monocytogenes and E. colipose a significant threat to food safety. In recent years, there has been an increase in the number of cases of Salmonella, E. coli and Listeria in food products. • Millions of cases of infections caused by foodborne microorganisms occur every year. • Problems with control: staff shortages (e.g. veterinarians), insufficient training of sanitary inspectors. • Polish food was reported as one of the most frequently contaminated in the EU: in 2017, 87 notifications of unsafe food were received from Poland, and in the following years these numbers increased, respectively in 2018 - 131 cases, in 2019 - 203 cases, in 2020 over 273 cases. • Growing demand for fast, accurate and affordable diagnostic tests in the food sector. Source: Food safety control system in Poland – current status and desired directions of changes 2020, Supreme Audit Office 18
Page 19
The State of the Microbiological Diagnostics Market • Reports of contamination of Polish products constitute 13 percent of cases worldwide. • In addition, the European Commission Audit showed that Sanitary Inspection inspectors did not have sufficient knowledge about taking swab samples to detect this bacteria. This is confirmed by the Report from the period 2017-2018, which indicates that 6.5% of veterinarians left work, which meant that over 60% of teams were unable to perform their tasks correctly. • Poland, which is the seventh largest food exporter in the EU with a result of over EUR 30 billion per year and is responsible for food safety both on the Polish and international markets, but does not have effective legal methods, nor does it take sufficient actions to guarantee the safety of food introduced to the market. 19 Source: Food safety control system in Poland – current status and desired directions of changes 2020, Supreme Audit Office
Page 20
Diagnostic methods Microbiological cultures waiting time from 48h to >21 days Rapid diagnostic tests low sensitivity and specificity complicated diagnostic process Genetic identification long waiting time >14 days, high cost of analysis Very often it is necessary to conduct pre-cultivation 20
Page 21
Diagnostic methods Salmonella •Standard:PN-EN ISO 6579-1:2017-04 •Methodology:multi-step detection process, including biochemical and serological confirmations •Duration:up to 7 days •Modern solutions:molecular methods (Real Time-PCR, LAMP) allowing to shorten the diagnostic time E. coli •Reference standard:ISO 13136 (for STEC) •Assistive techniques:identification of pathogenicity genes (molecular biology), cultivation on media •Other standards: • PN-ISO 16649-1, 16649-2, 16649-3 (determination of beta-glucuronidase-positive E. coli) • PN-ISO 4831, 4832 (determination of coliform bacteria) Listeria monocytogenes •Standards:PN-EN ISO 11290-1:2017-07, 11290-2:2017-07 •Process:preincubation, cultivation on selective media (ALOA, PALCALM) •Confirmatory tests:motility, hemolysis, carbohydrate breakdown 21
Page 22
Diagnostic methods Limit detection (CFU/g or ml) Time to obtain resultTest Type Sensitivity (%) Specificity (%) Cost (USD) PCR (reaction chain polymerases) 95-99 98-100 1-10 CFU/g 1-4 hours 15-50 ELISA-test 85-90 90-95 10^3-10^4 CFU/g 2-6 hours 5-20 Tests Immunochrome graphic Breeding bacterial 80-85 85-90 10^4-10^5 CFU/g 10-30 minutes 2-10 90-100 100 1-10 CFU/g 24-72 hours 1-5 22
Page 23
Market forecasts Market value:By 2030, the pathogen diagnostics market will grow to9 USD billion. Quick tests(mainly antigenic) will increase from USD 3 billion (2021) to USD 5.8 billion (2030). Growth of the molecular methods market:9% per annum. 23
Page 24
Q&A session
Page 25
investors@genomtec.com genomtec.com
Page 26
Genomtec ID: fast, cheap, portable, 5-pathogen test ❖ Genomtec ID –passive reaction card and simple design - a source of competitive advantage Cepheid, Gene Expert Visby Medical Binx Bosch Vivalytic Lucira Health Estimated price €35 Average price €35-50 Average price $50 Average price $60 - 75 Average price €50-80 Average price $40-45 Competitive cost production:without sensors, chips, components electronic and mobile Complex mechanical structure – including valves, bushings syringe, seals Disposable device with electronics and moving parts Complex construction – multi-layer system flow, membranes, PCB, electrodes Expensive cartridge with semiconductors and sensors Universal device disposable with electronics and heaters 26
Page 27
M&A Process Technology parameters sought by potential acquirers: Clairfield Partners – M&A Advisor has extensive experience in M&A transactions, including in the area of medical technology and biotechnology, including the genetic diagnostics sector. Competitive technology Confirmed action Objective: Establishing strategic partnerships, selling licenses and/or selling all or part of your intellectual property and the technology associated with it. uniqueness technology Planned activities: • identification and selection of potential buyers and partners. • preparation of necessary materials and establishment of contacts with global companies from, among others, the sector of medical devices for in vitro diagnostics • organization of the due diligence process, • shaping the negotiation strategy • coordinating the process of final talks related to a potential transaction efficiency production Efficiency confirmed in tests Scalability production 27